Immunoterapia (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Immunoterapia" in Italian language version.

refsWebsite

Global rank Italian rank

2^nd place

7^th place

4^th place

9^th place

799^th place

22^nd place

18^th place

104^th place

2web.archive.org

1^st place

1^st place

2semanticscholar.org

11^th place

2,598^th place

610^th place

820^th place

low place

low place

179^th place

499^th place

1,684^th place

2,574^th place

low place

low place

222^nd place

243^rd place

1frontiersin.org

4,679^th place

2,795^th place

485^th place

613^th place

cancer.gov

(EN) Immunotherapy for Cancer - NCI, su www.cancer.gov, 04/29/2015 - 08:00. URL consultato il 19 aprile 2024.

doi.org

dx.doi.org

De-novo and acquired resistance to immune checkpoint targeting, in The Lancet. Oncology, vol. 18, n. 12, December 2017, pp. e731–e741, DOI:10.1016/s1470-2045(17)30607-1, PMID 29208439.
(EN) Laura Conforti, The ion channel network in T lymphocytes, a target for immunotherapy, in Clinical Immunology, vol. 142, n. 2, 10 febbraio 2012, pp. 105-106, DOI:10.1016/j.clim.2011.11.009, PMID 22189042.
Masihi KN, Fighting infection using immunomodulatory agents, in Expert Opin Biol Ther, vol. 1, n. 4, July 2001, pp. 641-53, DOI:10.1517/14712598.1.4.641, PMID 11727500.
Immunotherapy for bladder cancer, in Research and Reports in Urology, vol. 7, 2015, pp. 65-79, DOI:10.2147/RRU.S63447, PMID 26000263.
Treatment of vulvar intraepithelial neoplasia with topical imiquimod, in N. Engl. J. Med., vol. 358, n. 14, April 2008, pp. 1465-73, DOI:10.1056/NEJMoa072685, PMID 18385498.
Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream, in J Low Genit Tract Dis, vol. 7, n. 4, October 2003, pp. 290-3, DOI:10.1097/00128360-200310000-00011, PMID 17051086.
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up, in Eur. Urol., vol. 56, n. 2, August 2009, pp. 260-5, DOI:10.1016/j.eururo.2009.04.009, PMID 19395154.
Immunotherapy for head and neck cancer, in Oral Oncol., vol. 45, n. 9, September 2009, pp. 747-51, DOI:10.1016/j.oraloncology.2009.02.009, PMID 19442565.
Extracorporeal photoimmunotherapy-photopheresis, in Front. Biosci., vol. 14, n. 14, 2009, pp. 4769-77, DOI:10.2741/3566, PMID 19273388.
Melanoma and immunotherapy, in Hematol. Oncol. Clin. North Am., vol. 23, n. 3, June 2009, pp. 547–64, ix–x, DOI:10.1016/j.hoc.2009.03.009, PMID 19464602.
Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic anti tumor effects, in J. Biomed. Sci., vol. 16, n. 1, 2009, p. 49, DOI:10.1186/1423-0127-16-49, PMID 19473507.
(DE) [Recurrent respiratory papillomatosis: indication for HPV vaccination?], in Dtsch. Med. Wochenschr., 134 Suppl 2, April 2009, pp. S100–2, DOI:10.1055/s-0029-1220219, PMID 19353471.
Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood, in Cancer Biol. Ther., vol. 8, n. 16, August 2009, pp. 1540-9, DOI:10.4161/cbt.8.16.8950, PMID 19471115.
Immunotherapy for the treatment of prostate cancer, in Nature Reviews Clinical Oncology, vol. 8, n. 9, September 2011, pp. 551-61, DOI:10.1038/nrclinonc.2011.72, PMID 21606971.
Adoptive cell transfer: A clinical path to effective cancer immunotherapy, in Nature Reviews Cancer, vol. 8, n. 4, April 2008, pp. 299-308, DOI:10.1038/nrc2355, PMID 18354418.
Cancer regression in patients after transfer of genetically engineered lymphocytes, in Science, vol. 314, n. 5796, October 2006, pp. 126-9, Bibcode:2006Sci...314..126M, DOI:10.1126/science.1129003, PMID 16946036.
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, in N. Engl. J. Med., vol. 358, n. 25, June 2008, pp. 2698-703, DOI:10.1056/NEJMoa0800251, PMID 18565862.
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells, in Journal of Immunology, vol. 174, n. 5, March 2005, pp. 2591-601, DOI:10.4049/jimmunol.174.5.2591, PMID 15728465.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, in J. Exp. Med., vol. 202, n. 7, October 2005, pp. 907-12, DOI:10.1084/jem.20050732, PMID 16203864.
T cell homeostatic proliferation elicits effective antitumor autoimmunity, in J. Clin. Invest., vol. 110, n. 2, July 2002, pp. 185-92, DOI:10.1172/JCI15175, PMID 12122110.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, in J. Clin. Oncol., vol. 26, n. 32, November 2008, pp. 5233-9, DOI:10.1200/JCO.2008.16.5449, PMID 18809613.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, in Science, vol. 298, n. 5594, October 2002, pp. 850-4, Bibcode:2002Sci...298..850D, DOI:10.1126/science.1076514, PMID 12242449.
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma, in J. Immunother., vol. 35, n. 8, October 2012, pp. 615-20, DOI:10.1097/CJI.0b013e31826e8f5f, PMID 22996367.
T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression., in Ann. Oncol., vol. 29, n. 7, April 2018, pp. 1575-1581, DOI:10.1093/annonc/mdy139, PMID 29688262.
Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report, in Case Rep. Oncol., vol. 5, n. 1, January 2012, pp. 114-8, DOI:10.1159/000337319, PMID 22666198.
Natural killer cells inhibit hepatitis C virus expression, in J. Leukoc. Biol., vol. 76, n. 6, December 2004, pp. 1171-9, DOI:10.1189/jlb.0604372, PMID 15339939.
Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity, in J. Immunother., vol. 34, n. 2, March 2011, pp. 129-38, DOI:10.1097/CJI.0b013e3182048c4e, PMID 21304407.
Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections, in Int. Rev. Immunol., vol. 27, n. 3, 2008, pp. 93-110, DOI:10.1080/08830180801911743, PMID 18437601.
alpha-Interferon treatment of patients with chronic fatigue syndrome, in Immunol. Invest., vol. 25, 1–2, 1996, pp. 153-64, DOI:10.3109/08820139609059298, PMID 8675231.
Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome, in Clin. Infect. Dis., 18 Suppl 1, January 1994, pp. S157–9, DOI:10.1093/clinids/18.Supplement_1.S157, PMID 8148445.
Killing of human Herpes virus 6-infected cells by lymphocytes cultured with interleukin-2 or -12, in Pediatr. Int., vol. 42, n. 6, December 2000, pp. 631-6, DOI:10.1046/j.1442-200x.2000.01315.x, PMID 11192519.
The immune tolerance network: a new paradigm for developing tolerance-inducing therapies, in The Journal of Allergy and Clinical Immunology, vol. 110, n. 1, July 2002, pp. 17-23, DOI:10.1067/mai.2002.124258, PMID 12110811.
Long-term clinical efficacy of grass-pollen immunotherapy, in N. Engl. J. Med., vol. 341, n. 7, August 1999, pp. 468-75, DOI:10.1056/NEJM199908123410702, PMID 10441602.
Chenglong Liu, Mengxuan Yang e Daizhou Zhang, Clinical cancer immunotherapy: Current progress and prospects, in Frontiers in Immunology, vol. 13, 2022, pp. 961805, DOI:10.3389/fimmu.2022.961805. URL consultato il 19 aprile 2024.
(EN) Romualdo Barroso‐Sousa, Patrick A. Ott e F. Stephen Hodi, Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management, in Cancer, vol. 124, n. 6, 15 marzo 2018, pp. 1111–1121, DOI:10.1002/cncr.31200. URL consultato il 19 aprile 2024.
Hanna Karhapää, Siru Mäkelä e Hanna Laurén, Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma, in Endocrine Connections, vol. 11, n. 2, 4 febbraio 2022, pp. e210562, DOI:10.1530/EC-21-0562. URL consultato il 19 aprile 2024.
Alexandra Chera, Andreea Lucia Stancu e Octavian Bucur, Thyroid-related adverse events induced by immune checkpoint inhibitors, in Frontiers in Endocrinology, vol. 13, 20 settembre 2022, DOI:10.3389/fendo.2022.1010279. URL consultato il 19 aprile 2024.
(EN) Irfan Vardarli, Susanne Tan e Tim Brandenburg, Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials, in The Journal of Clinical Endocrinology & Metabolism, vol. 109, n. 4, 15 marzo 2024, pp. 1132–1144, DOI:10.1210/clinem/dgad670. URL consultato il 19 aprile 2024.
(EN) M. Atkinson e A.J. Lansdown, Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy, in Best Practice & Research Clinical Endocrinology & Metabolism, vol. 36, n. 3, 2022-05, pp. 101635, DOI:10.1016/j.beem.2022.101635. URL consultato il 19 aprile 2024.
(EN) Maria Chiara Zatelli, Antongiulio Faggiano e Antonella Argentiero, Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group, in Cancer Treatment Reviews, vol. 126, 2024-05, pp. 102734, DOI:10.1016/j.ctrv.2024.102734. URL consultato il 19 aprile 2024.
Association between parasite infection and immune responses in multiple sclerosis, in Annals of Neurology, vol. 61, n. 2, February 2007, pp. 97-108, DOI:10.1002/ana.21067, PMID 17230481.
A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors, in Gut, vol. 55, n. 1, January 2006, pp. 136-7, DOI:10.1136/gut.2005.079129, PMID 16344586.
An update on the use of helminths to treat Crohn's and other autoimmunune diseases, in Parasitol. Res., vol. 104, n. 2, January 2009, pp. 217-21, DOI:10.1007/s00436-008-1297-5, PMID 19050918.
(FR) [Helminths and inflammatory bowel diseases], in Gastroenterol. Clin. Biol., vol. 32, n. 12, December 2008, pp. 1064-74, DOI:10.1016/j.gcb.2008.04.030, PMID 18619749.
Parasitic worms and inflammatory diseases, in Parasite Immunol., vol. 28, n. 10, October 2006, pp. 515-23, DOI:10.1111/j.1365-3024.2006.00879.x, PMID 16965287.
Human Hookworm Infection in the 21st Century, in Advances in Parasitology, vol. 58, 2004, pp. 197-288, DOI:10.1016/S0065-308X(04)58004-1, ISBN 978-0-12-031758-5.
Necator americanus infection: a possible cause of altered dendritic cell differentiation and eosinophil profile in chronically infected individuals, in PLoS Negl. Trop. Dis., vol. 3, n. 3, 2009, pp. e399, DOI:10.1371/journal.pntd.0000399, PMID 19308259.
Review series on helminths, immune modulation and the hygiene hypothesis: mechanisms underlying helminth modulation of dendritic cell function, in Immunology, vol. 126, n. 1, January 2009, pp. 28-34, DOI:10.1111/j.1365-2567.2008.03008.x, PMID 19120496.
Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions, in J. Exp. Med., vol. 206, n. 6, June 2009, pp. 1395-408, DOI:10.1084/jem.20082779, PMID 19468064.

elsevier.com

linkinghub.elsevier.com

(EN) M. Atkinson e A.J. Lansdown, Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy, in Best Practice & Research Clinical Endocrinology & Metabolism, vol. 36, n. 3, 2022-05, pp. 101635, DOI:10.1016/j.beem.2022.101635. URL consultato il 19 aprile 2024.
(EN) Maria Chiara Zatelli, Antongiulio Faggiano e Antonella Argentiero, Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group, in Cancer Treatment Reviews, vol. 126, 2024-05, pp. 102734, DOI:10.1016/j.ctrv.2024.102734. URL consultato il 19 aprile 2024.

frontiersin.org

Alexandra Chera, Andreea Lucia Stancu e Octavian Bucur, Thyroid-related adverse events induced by immune checkpoint inhibitors, in Frontiers in Endocrinology, vol. 13, 20 settembre 2022, DOI:10.3389/fendo.2022.1010279. URL consultato il 19 aprile 2024.

harvard.edu

adsabs.harvard.edu

Cancer regression in patients after transfer of genetically engineered lymphocytes, in Science, vol. 314, n. 5796, October 2006, pp. 126-9, Bibcode:2006Sci...314..126M, DOI:10.1126/science.1129003, PMID 16946036.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, in Science, vol. 298, n. 5594, October 2002, pp. 850-4, Bibcode:2002Sci...298..850D, DOI:10.1126/science.1076514, PMID 12242449.

icsmaugeri.it

Effetti avversi da farmaci | ICS Maugeri, su www.icsmaugeri.it. URL consultato il 19 aprile 2024.

mskcc.org

Immunotherapy | Memorial Sloan Kettering Cancer Center, su www.mskcc.org. URL consultato il 27 luglio 2017.

nih.gov

ncbi.nlm.nih.gov

De-novo and acquired resistance to immune checkpoint targeting, in The Lancet. Oncology, vol. 18, n. 12, December 2017, pp. e731–e741, DOI:10.1016/s1470-2045(17)30607-1, PMID 29208439.
(EN) Laura Conforti, The ion channel network in T lymphocytes, a target for immunotherapy, in Clinical Immunology, vol. 142, n. 2, 10 febbraio 2012, pp. 105-106, DOI:10.1016/j.clim.2011.11.009, PMID 22189042.
Masihi KN, Fighting infection using immunomodulatory agents, in Expert Opin Biol Ther, vol. 1, n. 4, July 2001, pp. 641-53, DOI:10.1517/14712598.1.4.641, PMID 11727500.
Immunotherapy for bladder cancer, in Research and Reports in Urology, vol. 7, 2015, pp. 65-79, DOI:10.2147/RRU.S63447, PMID 26000263.
Treatment of vulvar intraepithelial neoplasia with topical imiquimod, in N. Engl. J. Med., vol. 358, n. 14, April 2008, pp. 1465-73, DOI:10.1056/NEJMoa072685, PMID 18385498.
Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream, in J Low Genit Tract Dis, vol. 7, n. 4, October 2003, pp. 290-3, DOI:10.1097/00128360-200310000-00011, PMID 17051086.
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up, in Eur. Urol., vol. 56, n. 2, August 2009, pp. 260-5, DOI:10.1016/j.eururo.2009.04.009, PMID 19395154.
Immunotherapy for head and neck cancer, in Oral Oncol., vol. 45, n. 9, September 2009, pp. 747-51, DOI:10.1016/j.oraloncology.2009.02.009, PMID 19442565.
Extracorporeal photoimmunotherapy-photopheresis, in Front. Biosci., vol. 14, n. 14, 2009, pp. 4769-77, DOI:10.2741/3566, PMID 19273388.
Melanoma and immunotherapy, in Hematol. Oncol. Clin. North Am., vol. 23, n. 3, June 2009, pp. 547–64, ix–x, DOI:10.1016/j.hoc.2009.03.009, PMID 19464602.
Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic anti tumor effects, in J. Biomed. Sci., vol. 16, n. 1, 2009, p. 49, DOI:10.1186/1423-0127-16-49, PMID 19473507.
(DE) [Recurrent respiratory papillomatosis: indication for HPV vaccination?], in Dtsch. Med. Wochenschr., 134 Suppl 2, April 2009, pp. S100–2, DOI:10.1055/s-0029-1220219, PMID 19353471.
Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood, in Cancer Biol. Ther., vol. 8, n. 16, August 2009, pp. 1540-9, DOI:10.4161/cbt.8.16.8950, PMID 19471115.
Immunotherapy for the treatment of prostate cancer, in Nature Reviews Clinical Oncology, vol. 8, n. 9, September 2011, pp. 551-61, DOI:10.1038/nrclinonc.2011.72, PMID 21606971.
Adoptive cell transfer: A clinical path to effective cancer immunotherapy, in Nature Reviews Cancer, vol. 8, n. 4, April 2008, pp. 299-308, DOI:10.1038/nrc2355, PMID 18354418.
Cancer regression in patients after transfer of genetically engineered lymphocytes, in Science, vol. 314, n. 5796, October 2006, pp. 126-9, Bibcode:2006Sci...314..126M, DOI:10.1126/science.1129003, PMID 16946036.
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, in N. Engl. J. Med., vol. 358, n. 25, June 2008, pp. 2698-703, DOI:10.1056/NEJMoa0800251, PMID 18565862.
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells, in Journal of Immunology, vol. 174, n. 5, March 2005, pp. 2591-601, DOI:10.4049/jimmunol.174.5.2591, PMID 15728465.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, in J. Exp. Med., vol. 202, n. 7, October 2005, pp. 907-12, DOI:10.1084/jem.20050732, PMID 16203864.
T cell homeostatic proliferation elicits effective antitumor autoimmunity, in J. Clin. Invest., vol. 110, n. 2, July 2002, pp. 185-92, DOI:10.1172/JCI15175, PMID 12122110.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, in J. Clin. Oncol., vol. 26, n. 32, November 2008, pp. 5233-9, DOI:10.1200/JCO.2008.16.5449, PMID 18809613.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, in Science, vol. 298, n. 5594, October 2002, pp. 850-4, Bibcode:2002Sci...298..850D, DOI:10.1126/science.1076514, PMID 12242449.
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma, in J. Immunother., vol. 35, n. 8, October 2012, pp. 615-20, DOI:10.1097/CJI.0b013e31826e8f5f, PMID 22996367.
T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression., in Ann. Oncol., vol. 29, n. 7, April 2018, pp. 1575-1581, DOI:10.1093/annonc/mdy139, PMID 29688262.
Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report, in Case Rep. Oncol., vol. 5, n. 1, January 2012, pp. 114-8, DOI:10.1159/000337319, PMID 22666198.
Natural killer cells inhibit hepatitis C virus expression, in J. Leukoc. Biol., vol. 76, n. 6, December 2004, pp. 1171-9, DOI:10.1189/jlb.0604372, PMID 15339939.
Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity, in J. Immunother., vol. 34, n. 2, March 2011, pp. 129-38, DOI:10.1097/CJI.0b013e3182048c4e, PMID 21304407.
Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections, in Int. Rev. Immunol., vol. 27, n. 3, 2008, pp. 93-110, DOI:10.1080/08830180801911743, PMID 18437601.
alpha-Interferon treatment of patients with chronic fatigue syndrome, in Immunol. Invest., vol. 25, 1–2, 1996, pp. 153-64, DOI:10.3109/08820139609059298, PMID 8675231.
Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome, in Clin. Infect. Dis., 18 Suppl 1, January 1994, pp. S157–9, DOI:10.1093/clinids/18.Supplement_1.S157, PMID 8148445.
Killing of human Herpes virus 6-infected cells by lymphocytes cultured with interleukin-2 or -12, in Pediatr. Int., vol. 42, n. 6, December 2000, pp. 631-6, DOI:10.1046/j.1442-200x.2000.01315.x, PMID 11192519.
The immune tolerance network: a new paradigm for developing tolerance-inducing therapies, in The Journal of Allergy and Clinical Immunology, vol. 110, n. 1, July 2002, pp. 17-23, DOI:10.1067/mai.2002.124258, PMID 12110811.
Long-term clinical efficacy of grass-pollen immunotherapy, in N. Engl. J. Med., vol. 341, n. 7, August 1999, pp. 468-75, DOI:10.1056/NEJM199908123410702, PMID 10441602.
Association between parasite infection and immune responses in multiple sclerosis, in Annals of Neurology, vol. 61, n. 2, February 2007, pp. 97-108, DOI:10.1002/ana.21067, PMID 17230481.
A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors, in Gut, vol. 55, n. 1, January 2006, pp. 136-7, DOI:10.1136/gut.2005.079129, PMID 16344586.
An update on the use of helminths to treat Crohn's and other autoimmunune diseases, in Parasitol. Res., vol. 104, n. 2, January 2009, pp. 217-21, DOI:10.1007/s00436-008-1297-5, PMID 19050918.
(FR) [Helminths and inflammatory bowel diseases], in Gastroenterol. Clin. Biol., vol. 32, n. 12, December 2008, pp. 1064-74, DOI:10.1016/j.gcb.2008.04.030, PMID 18619749.
Parasitic worms and inflammatory diseases, in Parasite Immunol., vol. 28, n. 10, October 2006, pp. 515-23, DOI:10.1111/j.1365-3024.2006.00879.x, PMID 16965287.
Necator americanus infection: a possible cause of altered dendritic cell differentiation and eosinophil profile in chronically infected individuals, in PLoS Negl. Trop. Dis., vol. 3, n. 3, 2009, pp. e399, DOI:10.1371/journal.pntd.0000399, PMID 19308259.
Review series on helminths, immune modulation and the hygiene hypothesis: mechanisms underlying helminth modulation of dendritic cell function, in Immunology, vol. 126, n. 1, January 2009, pp. 28-34, DOI:10.1111/j.1365-2567.2008.03008.x, PMID 19120496.
Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions, in J. Exp. Med., vol. 206, n. 6, June 2009, pp. 1395-408, DOI:10.1084/jem.20082779, PMID 19468064.

pubmed.ncbi.nlm.nih.gov

Chenglong Liu, Mengxuan Yang e Daizhou Zhang, Clinical cancer immunotherapy: Current progress and prospects, in Frontiers in Immunology, vol. 13, 2022, pp. 961805, DOI:10.3389/fimmu.2022.961805. URL consultato il 19 aprile 2024.
Hanna Karhapää, Siru Mäkelä e Hanna Laurén, Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma, in Endocrine Connections, vol. 11, n. 2, 4 febbraio 2022, pp. e210562, DOI:10.1530/EC-21-0562. URL consultato il 19 aprile 2024.

oadoi.org

De-novo and acquired resistance to immune checkpoint targeting, in The Lancet. Oncology, vol. 18, n. 12, December 2017, pp. e731–e741, DOI:10.1016/s1470-2045(17)30607-1, PMID 29208439.
(EN) Laura Conforti, The ion channel network in T lymphocytes, a target for immunotherapy, in Clinical Immunology, vol. 142, n. 2, 10 febbraio 2012, pp. 105-106, DOI:10.1016/j.clim.2011.11.009, PMID 22189042.
Masihi KN, Fighting infection using immunomodulatory agents, in Expert Opin Biol Ther, vol. 1, n. 4, July 2001, pp. 641-53, DOI:10.1517/14712598.1.4.641, PMID 11727500.
Immunotherapy for bladder cancer, in Research and Reports in Urology, vol. 7, 2015, pp. 65-79, DOI:10.2147/RRU.S63447, PMID 26000263.
Treatment of vulvar intraepithelial neoplasia with topical imiquimod, in N. Engl. J. Med., vol. 358, n. 14, April 2008, pp. 1465-73, DOI:10.1056/NEJMoa072685, PMID 18385498.
Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream, in J Low Genit Tract Dis, vol. 7, n. 4, October 2003, pp. 290-3, DOI:10.1097/00128360-200310000-00011, PMID 17051086.
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up, in Eur. Urol., vol. 56, n. 2, August 2009, pp. 260-5, DOI:10.1016/j.eururo.2009.04.009, PMID 19395154.
Immunotherapy for head and neck cancer, in Oral Oncol., vol. 45, n. 9, September 2009, pp. 747-51, DOI:10.1016/j.oraloncology.2009.02.009, PMID 19442565.
Extracorporeal photoimmunotherapy-photopheresis, in Front. Biosci., vol. 14, n. 14, 2009, pp. 4769-77, DOI:10.2741/3566, PMID 19273388.
Melanoma and immunotherapy, in Hematol. Oncol. Clin. North Am., vol. 23, n. 3, June 2009, pp. 547–64, ix–x, DOI:10.1016/j.hoc.2009.03.009, PMID 19464602.
Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic anti tumor effects, in J. Biomed. Sci., vol. 16, n. 1, 2009, p. 49, DOI:10.1186/1423-0127-16-49, PMID 19473507.
(DE) [Recurrent respiratory papillomatosis: indication for HPV vaccination?], in Dtsch. Med. Wochenschr., 134 Suppl 2, April 2009, pp. S100–2, DOI:10.1055/s-0029-1220219, PMID 19353471.
Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood, in Cancer Biol. Ther., vol. 8, n. 16, August 2009, pp. 1540-9, DOI:10.4161/cbt.8.16.8950, PMID 19471115.
Immunotherapy for the treatment of prostate cancer, in Nature Reviews Clinical Oncology, vol. 8, n. 9, September 2011, pp. 551-61, DOI:10.1038/nrclinonc.2011.72, PMID 21606971.
Adoptive cell transfer: A clinical path to effective cancer immunotherapy, in Nature Reviews Cancer, vol. 8, n. 4, April 2008, pp. 299-308, DOI:10.1038/nrc2355, PMID 18354418.
Cancer regression in patients after transfer of genetically engineered lymphocytes, in Science, vol. 314, n. 5796, October 2006, pp. 126-9, Bibcode:2006Sci...314..126M, DOI:10.1126/science.1129003, PMID 16946036.
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, in N. Engl. J. Med., vol. 358, n. 25, June 2008, pp. 2698-703, DOI:10.1056/NEJMoa0800251, PMID 18565862.
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells, in Journal of Immunology, vol. 174, n. 5, March 2005, pp. 2591-601, DOI:10.4049/jimmunol.174.5.2591, PMID 15728465.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, in J. Exp. Med., vol. 202, n. 7, October 2005, pp. 907-12, DOI:10.1084/jem.20050732, PMID 16203864.
T cell homeostatic proliferation elicits effective antitumor autoimmunity, in J. Clin. Invest., vol. 110, n. 2, July 2002, pp. 185-92, DOI:10.1172/JCI15175, PMID 12122110.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, in J. Clin. Oncol., vol. 26, n. 32, November 2008, pp. 5233-9, DOI:10.1200/JCO.2008.16.5449, PMID 18809613.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, in Science, vol. 298, n. 5594, October 2002, pp. 850-4, Bibcode:2002Sci...298..850D, DOI:10.1126/science.1076514, PMID 12242449.
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma, in J. Immunother., vol. 35, n. 8, October 2012, pp. 615-20, DOI:10.1097/CJI.0b013e31826e8f5f, PMID 22996367.
T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression., in Ann. Oncol., vol. 29, n. 7, April 2018, pp. 1575-1581, DOI:10.1093/annonc/mdy139, PMID 29688262.
Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report, in Case Rep. Oncol., vol. 5, n. 1, January 2012, pp. 114-8, DOI:10.1159/000337319, PMID 22666198.
Natural killer cells inhibit hepatitis C virus expression, in J. Leukoc. Biol., vol. 76, n. 6, December 2004, pp. 1171-9, DOI:10.1189/jlb.0604372, PMID 15339939.
Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity, in J. Immunother., vol. 34, n. 2, March 2011, pp. 129-38, DOI:10.1097/CJI.0b013e3182048c4e, PMID 21304407.
Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections, in Int. Rev. Immunol., vol. 27, n. 3, 2008, pp. 93-110, DOI:10.1080/08830180801911743, PMID 18437601.
alpha-Interferon treatment of patients with chronic fatigue syndrome, in Immunol. Invest., vol. 25, 1–2, 1996, pp. 153-64, DOI:10.3109/08820139609059298, PMID 8675231.
Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome, in Clin. Infect. Dis., 18 Suppl 1, January 1994, pp. S157–9, DOI:10.1093/clinids/18.Supplement_1.S157, PMID 8148445.
Killing of human Herpes virus 6-infected cells by lymphocytes cultured with interleukin-2 or -12, in Pediatr. Int., vol. 42, n. 6, December 2000, pp. 631-6, DOI:10.1046/j.1442-200x.2000.01315.x, PMID 11192519.
Association between parasite infection and immune responses in multiple sclerosis, in Annals of Neurology, vol. 61, n. 2, February 2007, pp. 97-108, DOI:10.1002/ana.21067, PMID 17230481.
A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors, in Gut, vol. 55, n. 1, January 2006, pp. 136-7, DOI:10.1136/gut.2005.079129, PMID 16344586.
An update on the use of helminths to treat Crohn's and other autoimmunune diseases, in Parasitol. Res., vol. 104, n. 2, January 2009, pp. 217-21, DOI:10.1007/s00436-008-1297-5, PMID 19050918.
(FR) [Helminths and inflammatory bowel diseases], in Gastroenterol. Clin. Biol., vol. 32, n. 12, December 2008, pp. 1064-74, DOI:10.1016/j.gcb.2008.04.030, PMID 18619749.
Parasitic worms and inflammatory diseases, in Parasite Immunol., vol. 28, n. 10, October 2006, pp. 515-23, DOI:10.1111/j.1365-3024.2006.00879.x, PMID 16965287.
Necator americanus infection: a possible cause of altered dendritic cell differentiation and eosinophil profile in chronically infected individuals, in PLoS Negl. Trop. Dis., vol. 3, n. 3, 2009, pp. e399, DOI:10.1371/journal.pntd.0000399, PMID 19308259.
Review series on helminths, immune modulation and the hygiene hypothesis: mechanisms underlying helminth modulation of dendritic cell function, in Immunology, vol. 126, n. 1, January 2009, pp. 28-34, DOI:10.1111/j.1365-2567.2008.03008.x, PMID 19120496.
Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions, in J. Exp. Med., vol. 206, n. 6, June 2009, pp. 1395-408, DOI:10.1084/jem.20082779, PMID 19468064.

oup.com

academic.oup.com

(EN) Irfan Vardarli, Susanne Tan e Tim Brandenburg, Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials, in The Journal of Clinical Endocrinology & Metabolism, vol. 109, n. 4, 15 marzo 2024, pp. 1132–1144, DOI:10.1210/clinem/dgad670. URL consultato il 19 aprile 2024.

semanticscholar.org

The immune tolerance network: a new paradigm for developing tolerance-inducing therapies, in The Journal of Allergy and Clinical Immunology, vol. 110, n. 1, July 2002, pp. 17-23, DOI:10.1067/mai.2002.124258, PMID 12110811.
Long-term clinical efficacy of grass-pollen immunotherapy, in N. Engl. J. Med., vol. 341, n. 7, August 1999, pp. 468-75, DOI:10.1056/NEJM199908123410702, PMID 10441602.

stanford.edu

med.stanford.edu

Clinical Trials Search Results - Stanford University School of Medicine, su med.stanford.edu. URL consultato il 3 aprile 2016.

web.archive.org

2008 Symposium Program & Speakers, su cancerresearch.org, Cancer Research Institute (archiviato dall'url originale il 15 ottobre 2008).
Roger Highfield, Cancer patient recovers after injection of immune cells (XML), in The Telegraph, 18 giugno 2008. URL consultato il 22 dicembre 2019 (archiviato dall'url originale il 12 settembre 2008).

wiley.com

acsjournals.onlinelibrary.wiley.com

(EN) Romualdo Barroso‐Sousa, Patrick A. Ott e F. Stephen Hodi, Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management, in Cancer, vol. 124, n. 6, 15 marzo 2018, pp. 1111–1121, DOI:10.1002/cncr.31200. URL consultato il 19 aprile 2024.